Predictive oncology appoints leading biopharma executive matthew j. hawryluk ph.d.

Eagan, minn., dec. 05, 2022 (globe newswire) -- predictive oncology inc. (nasdaq: poai) is pleased to announce the appointment of matthew j. hawryluk, ph.d., (www.predictive-oncology.com) to its board of directors to help support the company's strategic initiatives and commercialization efforts. dr. hawryluk currently serves as executive vice president and chief business officer of gritstone bio, inc (nasdaq: grts).
POAI Ratings Summary
POAI Quant Ranking